D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: A meta-analysis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2101-2117

  Xia, Jing ^a   Du, Yanqiu ^b   Han, Jiyang ^a   Liu, Guo ^a   Wang, Xumei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang Ninth People's Hospital   (China)

Author keywords

Clinical Global Impression Severity Scale (CGI S); D cycloserine; Exposure and response prevention; Obsessive compulsive disorder; Yale Brown Obsessive Compulsive Scale (Y BOCS)

Indexed keywords

CYCLOSERINE; PLACEBO;

ARTICLE; BEHAVIOR THERAPY; CLINICAL GLOBAL IMPRESSION SCALE; EXPOSURE AND RESPONSE PREVENTION; FOLLOW UP; HUMAN; META ANALYSIS; OBSESSIVE COMPULSIVE DISORDER; REMISSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE; MULTIMODALITY CANCER THERAPY; OBSESSIVE-COMPULSIVE DISORDER; PROCEDURES;

BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; TREATMENT OUTCOME;

EID: 84929224003     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S68994     Document Type: Article

References (56)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
3. Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int Rev Psychiatry. 2003;15(1-2):178-184.
4. Jenike MA. Clinical practice. Obsessive-compulsive disorder. N Engl J Med. 2004; 350(3):259-265.
5. Storch EA, Merlo LJ. Obsessive-compulsive disorder: strategies for using CBT and pharmacotherapy. J Fam Pract. 2006;55(4):329-333.
6. Blier P, Habib R, Flament MF. Pharmacotherapies in the management of obsessive-compulsive disorder. Can J Psychiatry. 2006;51(7): 417-430.
7. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2006;29(2):553-584, xi.
8. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2007;22(4):230-237.
9. Davis M. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: clinical implications for exposure therapy. Eur J Neurosci. 2002;16(3):395-398.
10. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126.
11. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369-375.
12. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61(11):1136-1144.
13. Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev. 2006;12(3-4):208-217.
14. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry. 2008;63(6):544-549.
15. Otto MW, Tolin DF, Simon NM, et al. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010;67(4):365-370.
16. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):335-341; quiz 409.
17. Kushner MG, Kim SW, Donahue C, et al. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry. 2007;62(8):835-838.
18. Farrell LJ, Waters AM, Boschen MJ, et al. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety. 2013;30(8):723-731.
19. Storch EA, Murphy TK, Goodman WK, et al. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010;68(11):1073-1076.
20. Mataix-Cols D, Turner C, Monzani B, et al. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry. 2014;204(1):77-78.
21. Bontempo A, Panza KE, Bloch MH. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J Clin Psychiatry. 2012;73(4):533-537.
22. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012-1016.
23. Storch EA, Shapira NA, Dimoulas E, Geffken GR, Murphy TK, Goodman WK. Yale-Brown Obsessive Compulsive Scale: the dimensional structure revisited. Depress Anxiety. 2005;22(1):28-35.
24. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(7):1133-1139.
25. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis [webpage on the Internet]. Ottawa, Ontario; Ottawa Health Research Institute; 2004. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed December 15, 2013.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
27. Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51-61.
28. Navarro-Mateu F, Escámez T, Koenen KC, Alonso J, Sánchez-Meca J. Meta-analyses of the 5-HTTLPR polymorphisms and post-traumatic stress disorder. PLoS One. 2013;8(6):e66227.
29. Rapp A, Dodds A, Walkup JT, Rynn M. Treatment of pediatric anxiety disorders. Ann N Y Acad Sci. 2013;1304(1):52-61.
30. Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ. Obsessive compulsive disorder and the glutamatergic system. Curr Opin Psychiatry. 2014;27(1):32-37.
31. Grados MA, Specht MW, Sung HM, Fortune D. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin Drug Discov. 2013;8(12):1515-1527.
32. Davis M. NMDA receptors and fear extinction: implications for cognitive behavioral therapy. Dialogues Clin Neurosci. 2011;13(4):463-474.
33. Vloet TD, Simons M, Herpertz-Dahlmann B. [Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder]. Z Kinder Jugendpsychiatr Psychother. 2012;40(1):29-39; quiz 39. German.
34. Walsh KH, McDougle CJ. Psychotherapy and medication management strategies for obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2011;7:485-494.
35. Choi DC, Rothbaum BO, Gerardi M, Ressler KJ. Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder. Curr Top Behav Neurosci. 2010;2:279-299.
36. Ganasen KA, Ipser JC, Stein DJ. Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr Clin North Am. 2010;33(3):687-699.
37. Singer HS, Morris C, Grados M. Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses. 2010;74(5):862-867.
38. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374(9688):491-499.
39. Storch EA, Mariaskin A, Murphy TK. Psychotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep. 2009;11(4):296-301.
40. Figee M, Denys D. New pharmacotherapeutic approaches to obsessive-compulsive disorder. CNS Spectr. 2009;14(2 Suppl 3):13-23.
41. Tryon WW, McKay D. Memory modification as an outcome variable in anxiety disorder treatment. J Anxiety Disord. 2009;23(4):546-556.
42. Amaral OB, Roesler R. Targeting the NMDA receptor for fear-related disorders. Recent Pat CNS Drug Discov. 2008;3(3):166-178.
43. Rothbaum BO. Critical parameters for D-cycloserine enhancement of cognitive-behaviorial therapy for obsessive-compulsive disorder. Am J Psychiatry. 2008;165(3):293-296.
44. Hofmann SG. Enhancing exposure-based therapy from a translational research perspective. Behav Res Ther. 2007;45(9):1987-2001.
45. Siegmund A, Golfels F, Finck C, et al. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res. 2011;45(8):1042-1047.
46. Onur OA, Schlaepfer TE, Kukolja J, et al. The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry. 2010;67(12):1205-1211.
47. Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl). 2010;210(1):13-24.
48. Chasson GS, Buhlmann U, Tolin DF, et al. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther. 2010;48(7):675-679.
49. Shim SS, Hammonds MD, Vrabel MM. D-cycloserine augmentation for behavioral therapy. Am J Psychiatry. 2008;165(8):1050.
50. Guastella AJ, Lovibond PF, Dadds MR, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther. 2007;45(4):663-672.
51. First MB, Spitzer R, Gibbon M, Williams J. Structural Clinical Interview for Axis-I DSM-IV Disorders, Patient Edition (SCID-I/P Version 2.0). NewYork: Biometrics Research Department, New York State Psychiatric Institute. 1989.
52. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
53. Brown TA, Di Nardo PA, Barlow DH. Anxiety Disorders Interview Schedule for DSM-IV. Albany, New York: University of Albany. 1989.
54. Silverman WK, Albano AM. Anxiety Disorders Interview Schedule for DSM-IV-Child and Parent Versions. San Antonio, TX: Graywind Publications; 1996.
55. Scahill L, Riddle MA, McSwiggin-Hardin M, et al. Children’s Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry. 1997;36(6):844-852.
56. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Washington, DC: US Government Printing Office; 1976. Available from: https://ia600503.us.archive.org/10/items/ecdeuassessmentm1933guyw/ecdeuassessmentm1933guyw.pdf. Accessed December 15, 2013.